New Surrogate Marker for ADT Evaluation Proposed
Time interval free of biochemical failure may be a potential surrogate end point in the setting of androgen-deprivation therapy evaluation in men with prostate cancer.
Time interval free of biochemical failure may be a potential surrogate end point in the setting of androgen-deprivation therapy evaluation in men with prostate cancer.
Panobinostat plus bicalutamide increased radiographic progression-free survival in patients with CRPC resistant to second-line antiandrogen therapy.
Trade-offs should be carefully considered, as data have indicated that many QoL factors eventually even out.
Utilizing data from the PREVAIL dataset, researchers developed mathematical models that can provide prognostic information for men being treated with enzalutamide for chemotherapy-naïve metastatic castration-resistant prostate cancer.
Omega-3 fatty acids found in fish oil act through a host receptor, GPR120, to confer anti-prostate cancer effects. Additional studies are underway.
Radiotherapy may improve survival among men with low metastatic burden, but not in all patients with metastatic prostate cancer.
The regimen did not improve survival and increased bone fractures.
Findings from the SPARTAN trial show that HRQoL is not diminished by adding apalutamide to androgen deprivation therapy in men with asymptomatic, nonmetastatic CRPC.
Men treated with radical prostatectomy plus radiotherapy for locally or regionally advanced prostate cancer had improved survival but worse adverse events.
Differences in TMB between African and European patients show that “racial mutational disparity is not a technical or computational artifact,” according to authors.